

# Bruno Daniele

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9632145/publications.pdf>

Version: 2024-02-01

16  
papers

4,543  
citations

1040056

9  
h-index

940533

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

4526  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Anorectal and Genital Mucosal Melanoma: Diagnostic Challenges, Current Knowledge and Therapeutic Opportunities of Rare Melanomas. <i>Biomedicines</i> , 2022, 10, 150.   | 3.2  | 11        |
| 2  | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. <i>European Journal of Cancer</i> , 2022, 167, 1-12.                                     | 2.8  | 43        |
| 3  | BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.   | 4.1  | 40        |
| 4  | How to Treat Hepatocellular Carcinoma in Elderly Patients. <i>Pharmaceuticals</i> , 2021, 14, 233.   | 3.8  | 9         |
| 5  | Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein $\geq 400$ ng/mL: A Matching-Adjusted Indirect Comparison. <i>Advances in Therapy</i> , 2021, 38, 2472-2490.           |      | 9         |
| 6  | Bone Metastases from Gastric Cancer: What We Know and How to Deal with Them. <i>Journal of Clinical Medicine</i> , 2021, 10, 1777.   | 2.4  | 8         |
| 7  | The Enigmatic Role of TP53 in Germ Cell Tumours: Are We Missing Something?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7160.   | 4.1  | 4         |
| 8  | Epigenetic Regulation in Melanoma: Facts and Hopes. <i>Cells</i> , 2021, 10, 2048.   | 4.1  | 20        |
| 9  | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 193-202.  | 1.6  | 1,255     |
| 10 | Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. <i>Cancers</i> , 2020, 12, 3025.  | 3.7  | 55        |
| 11 | Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma. <i>Advances in Therapy</i> , 2020, 37, 2678-2695.  | 2.9  | 37        |
| 12 | From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.  | 3.7  | 7         |
| 13 | Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , 2020, 40, 2008-2020.   | 3.9  | 26        |
| 14 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased $\alpha$ -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 282-296. | 10.7 | 1,202     |
| 15 | Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 940-952.   | 10.7 | 1,816     |
| 16 | Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. <i>Cancers</i> , 2012, 4, 549-565.   | 3.7  | 1         |